New Year’s Day is unofficially the biggest shopping holiday of the year for fitness gear as people lean into their annual resolutions. But real deal seekers know that Cyber Monday is actually the best opportunity to score items like exercise equipment, activewear, fitness trackers, and sneakers at a steep discount.
Cyber Monday sales from retailers like Amazon, Walmart, and Nordstrom on brands like Lululemon, Adidas, and Mirror make it possible to outfit not only your home gym but your workout wardrobe — and all the other essentials needed to tackle your health and fitness goals.
Some of the best Cyber Monday fitness deals we’ve spotted so far include $50 off Amazon’s best-selling treadmill, $45 off an adjustable dumbbell set, and $60 off a stationary bike. Of course, nothing will go better with a fresh home gym setup than a new pair of leggings (like this Lululemon pair that’s 50 percent off) and a fitness tracker to maximize your workout (like this Suunto watch that’s 42 percent off).
And while many popular fitness items — like treadmills, stationary bikes, and dumbbells — tend to sell out around early January, they’re fully in-stock ahead of the holidays. Better yet, they actually make spectacular gifts for loved ones trying to make the most of their time spent social distancing this winter.
Ready to get your goals on? Shop the 35 best Cyber Monday 2020 fitness deals happening now.
Best Home Gym Equipment Deals
- Sunny Health and Fitness Folding Treadmill, $349.97 (orig. $399); amazon.com
- DDFE Adjustable Dumbbell 40.4lb Set, $183 (orig. $228); amazon.com
- YOSUDA Indoor Cycling Bike Stationary, $99.99 (orig. $199.99); amazon.com
- Bala Weighted Anklet Set, $34.30 (orig. $49); anthropologie.com
- TheraBand Resistance Band Set, $11.26 (orig. $15); amazon.com
- Heathyoga Eco Friendly Non Slip Yoga Mat, $29.96 (orig. $49.95); amazon.com
- Skonyon Adjustable 25lb Dumbbell, $99 (orig. $129); walmart.com
- Echelon Connect Sport Indoor Cycling Bike, $497 (orig. $599); walmart.com
- P. Volve Starter Kit, $112 (orig. $159.99); pvolve.com
Best Fitness Tracker Deals
- Suunto 9 GPS Sport Watch, $346.37 (orig. $599); amazon.com
- Apple Watch Series 5, $329 (orig. $429); amazon.com
- Fitbit Sense Advanced Smart Watch, $279.95 (orig. $329.95); amazon.com
- Polar Ignite Advance Waterproof Fitness Watch, $199.90 (orig. $229.95); amazon.com
- Garmin Instinct Rugged Outdoor Watch, $149.99 (orig. $299.99); amazon.com
Best Activewear Deals
- Colorfulkoala High-Waisted Yoga Pants, $20 (orig. $25); amazon.com
- Under Armour Women’s ColdGear Authentic Leggings, $35.99 (orig. $49.99); amazon.com
- Lululemon Fast and Free High Rise Tight 25″ Ice Dye, $69 (orig. $138); lululemon.com
- Spanx Booty Boost Active Leggings, $78.40 (orig. $98); spanx.com
- Alo Yoga Airbrush High-Waist 7/8 Leggings, $62 (orig. $78); aloyoga.com
- Wacoal High Impact Underwire Sports Bra, $27 (orig. $72); nordstrom.com
- Sweaty Betty Stamina Longline Sports Bra, $30.80 (orig. $44); sweatybetty.com
- Puma Women’s Women’s Solstice
(MENAFN – Baystreet.ca) Thousands of years ago, ancient Aztecs may have held the https://www.ncmh.info/2020/03/30/mental-health-and-magic-mushrooms/ key to the next biotech breakthrough.
During ceremonial rituals, they used a special compound they called “the flesh of the gods”…
And today, researchers are discovering that this same compound could transform how we approach mental health moving forward…
Sparking an explosion of interest in what some experts project could be a https://www.openpr.com/news/2068844/psychedelic-drugs-market-2020-to-grow-at-16-3-cagr-by-2027 $6.9 billion market by 2027
It’s already being studied in some of the top medical facilities in the United States, including Johns Hopkins University…
Where it was found that this chemical was up to https://www.npr.org/sections/health-shots/2020/11/04/931377532/rigorous-study-backs-a-psychedelic-treatment-for-major-depression 4x more effective in treating depression than typical antidepressants.
Source: https://www.beckleyfoundation.org/2016/05/17/magic-mushrooms-psilocybin-a-breakthrough-treatment-for-depression-from-the-beckleyimperial-research-programme/ BeckleyFoundation.org
Now, the media is taking the story mainstream as it continues to gain steam by the day.
CNN reported “One use of [this compound] https://www.cnn.com/2020/01/28/health/magic-mushrooms-psilocybin-cancer-patients-study-wellness/index.html reduces anxiety and depression in cancer patients.”
Fortune Magazine reported “Psychedelic drugs may https://fortune.com/longform/psychedelic-drugs-business-mental-health/ revolutionize mental health care.”
And https://www.cnbc.com/2020/11/04/oregon-becomes-first-state-to-legalize-magic-mushrooms-as-more-states-ease-drug-laws.html CNBC is reporting “Oregon becomes first state to legalize [the special compound] as more states ease drug laws in https://www.cnbc.com/2020/11/04/oregon-becomes-first-state-to-legalize-magic-mushrooms-as-more-states-ease-drug-laws.html ‘psychedelic renaissance'”
This could become one of the greatest transformations in mental health care we’ve seen in decades, with the potential to treat chronic conditions much faster than typical treatments.
And one company plowing ahead at the forefront of this breakthrough is Lobe Sciences Ltd. ( https://finance.yahoo.com/quote/LOBE.CN?p=LOBE.CN & .tsrc=fin-srch CSE:LOBE ; https://finance.yahoo.com/quote/GTSIF?p=GTSIF & .tsrc=fin-srch OTC:GTSIF ).
Earlier this year, they acquired Eleusian Biosciences Corp., another growing biotech company with several provisional patents to their name.
Between the treatments they’ve identified and devices they’re in the process of developing, they have the potential to own a significant share of this booming market.
And at a market cap of just https://finance.yahoo.com/quote/LOBE.CN?p=LOBE.CN & .tsrc=fin-srch C$8 million, this could be a major boom for early investors as news continues to break in this fascinating field.
Here are 5 reasons why you should be paying attention to Lobe Sciences ( https://finance.yahoo.com/quote/LOBE.CN?p=LOBE.CN & .tsrc=fin-srch CSE:LOBE ; https://finance.yahoo.com/quote/GTSIF?p=GTSIF & .tsrc=fin-srch OTC:GTSIF ).
#1 – The Massive Mental Health Market
In 2019, it was estimated that https://www.nimh.nih.gov/health/statistics/mental-illness.shtml#:~:text=Mental%20illnesses%20are%20common%20in,mild%20to%20moderate%20to%20severe. 1 in every 5 Americans lives with a mental illness, according to the National Institute of Mental Health.
And that was before the stress and uncertainty of living through a global pandemic.
That’s why the market for treating mental health and neurodegenerative disorders is projected to reach a whopping https://www.globenewswire.com/news-release/2019/07/26/1892319/0/en/Behavioural-Health-Market-Size-to-Hit-US-240-Bn-by-2026.html $240 billion by 2026.
But the transformative medicine movement could be poised to grab a huge share of that market based on early results.
These chemical compounds work in a completely different way than standard medications used today.
While most treatment approaches for mental health tend to focus on treating the symptoms, these compounds take a different approach.
They work by addressing the root cause of the issue by giving you a transformational experience that can help “reset” the brain…
Interrupting the thought patterns and habit loops in the brain that can get people stuck for months or years in many cases.
Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol | News
CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells. People with genetic variations that reduce PCSK9 function have lower LDL-C levels in the blood and a lower risk for major cardiovascular events. ION449 is a LIgand Conjugated Antisense (LICA) medicine being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.
The Phase 2b, randomized, double-blind, placebo-controlled trial will enroll approximately 108 participants, aged 18-75, who have LDL-C levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on blood cholesterol management. The primary objective is to assess the effect of different doses of ION449 on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy. The study will evaluate three dose levels of ION449 versus placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints. Learn more about the trial at: https://clinicaltrials.gov/ct2/show/NCT04641299.
In a Phase 1 study reported at the American Heart Association (AHA) Scientific Sessions on November 13, single subcutaneous doses of ION449 (AZD8233) demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90 percent and up to 70 percent, respectively, in subjects who had a baseline LDL-C between 100 and 190 mg/dL without concomitant statin therapy.1 Doses up to 120 mg were evaluated. ION449 was observed to be safe and well-tolerated at all dose levels.
“Results from the Phase 1 study showed that ION449 potently reduces PCSK9 and LDL cholesterol. ION449 demonstrated best-in-class potential for PCSK9 inhibition and LDL-C reduction, supporting larger clinical trials that are now underway to further evaluate efficacy and safety,” said Sotirios “Sam” Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis. “The growing evidence supporting Ionis’ advanced LICA technology in cardiovascular disease holds promise for more effective approaches to lower LDL-C and to address cardiovascular disease, the leading cause of death worldwide.”
Dr. Tsimikas will provide an update on Ionis’ cardiovascular programs during Ionis’ Virtual Investor Day, Dec. 7, 2020, beginning at 12 p.m. EST.
Ionis earned a milestone payment of $20 million from AstraZeneca for the Phase 2b clinical trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiometabolic disease and cancer.
About Ionis Pharmaceuticals, Inc.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our
The coronavirus pandemic doesn’t seem to have slowed construction in Houston, as concrete trucks traverse the freeways and cranes add layers to the Jengalike structures that ultimately become midrise and high-rise buildings.
There’s one underway now on Fannin Street next to the Mann Eye Institute at the point where Midtown gives way to the Museum District. Dr. Mike Mann goes to work each day and keeps track of the building — his latest project — by looking out his window.
From a conference room in his medical office building, Mann talks about his dream for a three-building complex that will include a new medical office building — the 10-story Museo, which broke ground earlier this year and has an anticipated price tag of $77 million — and, someday, a five-star hotel and then a residential high-rise, all centered around a parklike setting.
The three-story main office for his ophthalmology practice was built in 1979 and was likely thought of as sleek and stylish back then. But architecture has been taken up a notch in recent years, with modern design gaining traction in residential, commercial and hospitality sectors.
Marko Dasigenis, who once worked with architect Philip Johnson in New York and also worked in what is now the PJMD architecture offices in Houston, is the lead designer for Mann’s trio of buildings.
Mann sees Museo — and potentially the whole complex — as creating a beautiful new gateway to what lies beyond: Houston’s Museum of Fine Arts, Asia Society, Holocaust Museum and other cultural sites within walking distance. Newish modern residential buildings, the 24-story Southmore and the 8-story Mond, both are nearby as well.
On the surface, Museo’s architecture is strictly modern, with panels of blue-green glass for the exterior and, for the interior, slabs of pure white marble that Mann, Dasigenis and architectural colorist Carl Black flew to Macedonia in Greece to personally select. On the environmental side, the building will be Class A LEED certified.
“I love to restore vision, it is a passion. But I have always had a thing for real estate … and I like art,” said Mann, who started his medical practice 43 years ago. “My life has been wonderful, that I can practice ophthalmology and build the practice and now have a place where other people can practice medicine.”
The Mann Eye Institute will occupy the 10th floor of Museo, and the remaining space will be leased to other medical practices. Mann envisions the first floor as having a variety of uses intended to draw in the public.
Dasigenis said that the beauty of designing and constructing a medical office building now is that they’re able to accommodate the new, high-tech future that lies ahead. The formula of a building with 25,000 square feet per floor and a boxy exterior are a thing of the past.
Although Museo is the first of Mann’s ideas to be built, Dasigenis actually first designed the potential residential high-rise and established its design vocabulary based on analytical cubism,
Too often, traders tend to pigeonhole certain stocks. For example, some folks might think of Inovio Pharmaceuticals (NASDAQ:INO) as a Covid-19 vaccine company and INO stock as nothing more than a novel coronavirus stock.
Don’t get me wrong. Inovio absolutely is part of the nationwide and global battle against the coronavirus. But there’s no need to pigeonhole INO as just a coronavirus stock.
The company works diligently to develop DNA medicines to treat a range of infectious diseases and cancers. There’s positive news about Inovio’s development of its Covid-19 vaccine candidate, INO-4800, but there’s also good news in other departments.
Therefore, it’s worth investigating both Inovio’s Covid-19 vaccine efforts as well as the company’s progress in other areas. That way, you can get a complete picture of this fascinating biotech company with breakout potential.
INO Stock at a Glance
If the market is telling us anything about INO stock, it’s that the shares are underappreciated and undervalued. You might even say that INO is one of the biotech sector’s most compelling bargains at the moment.
INO stock achieved its 52-week high of $31.71 on June 29, but somehow the market decided that this wasn’t the right price for the stock. As a result, a gradual sell-off commenced.
At the close of Nov. 24, INO stock settled slightly above $10 per share. Sometimes people say that they like to buy low and sell high. When the time comes to buy a stake in a promising company at a low price, however, those same traders tend to chicken out.
If you hesitate, you might miss out on a rare opportunity with INO stock. Even if you’re only thinking relatively short-term (i.e., as a swing trader), there’s potential here. INO has a tendency to spike quickly from time to time, just like it did in mid-September. This could easily happen again if there’s good news.
Not Just Covid-19
I’m going to take a different approach from many commentators and veer away from the topic of Covid-19 vaccine candidates. Let’s not discount the significance of the other conditions that Inovio is working to address.
One example is INO-3107, Inovio’s DNA medicine candidate designed to treat Recurrent Respiratory Papillomatosis (RRP). Inovio just dosed its first subject with INO-3107 in a Phase 1/2 clinical trial for this condition.
RRP is a very unfortunate and rare ailment. Caused by certain types of human papillomavirus (HPV), RRP is incurable and causes non-cancerous tumor growths that lead to life-threatening airway obstructions.
Usually, surgery is used to treat RRP. Furthermore, sometimes patients need multiple surgeries, which can severely impact their quality of life. The U.S. Food and Drug Administration (FDA) already granted INO-3107 Orphan Drug Designation, so it’s great to hear that there’s progress in developing this less invasive treatment.
Advancing Other DNA Medicines
Like in America, the healthcare industry is also making shifts to adopt new, safer hospital practices in response to Covid-19. Since physical contact and proximity present such risks, hospitals are turning to a variety of digital tools in order to meet their care priorities, such as risk reduction and better resource utilization. Having a better understanding of these priorities and what tools hospitals are using now will help us in the health tech industry know what to build for them next.
At Siilo, we believe that putting tried and true technology into the hands of healthcare professionals will result in a higher quality of care for patients down the line. Here are the three major categories of care currently being aided by digital tools: distance diagnoses, internal communications, and external collaborations.
Covid-19 was not the start of the telehealth revolution, but it was certainly a major driver in its widespread adoption this year. While doctors and specialists could not and still cannot see their patients in person, that doesn’t mean people haven’t stopped needing consultations. Moving diagnoses online has been the only option to continue delivering care directly to patients.
Companies like Germany’s Klara are working to put these digital tools at the center of doctor-patient communication all across Europe. Telehealth services provide a variety of benefits: anything from patient portals, where individuals can email their doctors in a secure online environment, to mobile applications, allowing doctors to hold virtual appointments with patients via video call. They can also include the collection of health data, voluntarily given by patients, through the Internet of Things, such as smartwatches, in order to get a more holistic view of the patient’s wellbeing.
Advances in telehealth can certainly ease the burdens on healthcare professionals looking to safely diagnose their patients over digital platforms, but we need to make sure that we are providing products that prioritize data safety. That means designing for GDPR compliance incorporating key features, like passcode protection and device-only data storage.
The influx of telehealth and digital solutions for communicating with patients has also resulted in a professional counterpart for members of medical institutions, organizations, and associations all across Europe. Beyond the EHRs and secure email servers typically found in hospitals or physicians’ offices, technology is being developed to make communication by modern healthcare professionals more efficient, more secure, and more informative.
People bring their smartphones to work with them, and as such, we see professionals increasingly seeking out mobile tools and applications to simplify their workflows. In particular, professionals are looking for ways to quickly exchange information with each other and their departments at large. My company, Siilo works in this space.
This integration is not seamless, however. Bring-your-own-device policies, such as those found in Germany and France, have been put in place to limit the chances of cross-contaminating patient data and personal information, and increasing digital literacy amongst professionals can be a difficult and time-consuming endeavor. Nevertheless, hospitals and public health institutions should be prepared
Aspetar, a sports medicine and orthopedic hospital, has announced a series of virtual forums based on the book “Aspetar sports medicine collection”, which will be organised from December until the Qatar 2022 World Cup starts.
The virtual forums will present healthcare professionals with the opportunity to interact and recognise the most important research, as well as many other topics on sports medicine that has made Aspetar an exemplary model in the world of sports medicine.
The “Aspetar Sports Medicine Collection” forum gives free access to information based on scientific evidence produced by the Aspetar scientific journal.
Running for two years
With the monthly celebration of the forum, starting from December 2020 until the start of the 2022 World Cup. Experts will discuss the 24 chapters of the book in just one month. The “Aspetar sports medicine collection” book was released in September.
The subject “Foot and ankle” will be the first to be addressed in detail in the first series of forums that begin on December 2, which will be led by Professor Piter Dokh, representative of Aspetar.
Several important topics of medicine and sports science will be addressed, including Hydration and Nutrition, Recovery Strategies, Sleep Problems and Long Trips, Sports Psychology, Heart Health, Pathology in Athletes, Ethics in Sports Medicine and Concussion in Sports.
The forums will be held on Microsoft Teams, which allows for visual and auditory communication between participants. Registration for the virtual forums can be done online, through the Aspetar site. Participants will also be able tojoin in on the Twitter hashtag to ask any questions that will be answered during the sessions.
It is also worth mentioning that Aspetar aims to present reliable, evidence-based information to a considerable numbers of readers interested in the sports and medical fields, as well as to help build awareness and knowledge locally, regionally or internationally. Aspetar’s vision is to be the universal pioneer in the fields of sports medicine, orthopedics, and rehabilitation, thanks to its elaborate world-class facilities, modern technologies and research.
(MENAFN – GlobeNewsWire – Nasdaq) OTTAWA, Nov. 30, 2020 (GLOBE NEWSWIRE) — The global [To enable links contact MENAFN] precision medicine market value surpassed USD 59.16 billion in 2019 and expected to reach USD 141.33 billion by 2027.
Precision medicine is an emerging approach of treatment and prevention of disease that takes into account the individual variability in environment, genes, and lifestyle for each person. This approach allows researchers and doctors to predict more precisely that which treatment and prevention strategies for a particular disease will work on the specified groups of people.
Although the term “precision medicine” is currently new to the consumers, the concept has been a part of healthcare industry for many years. For instance, a person who requires a blood transfusion is not given blood from any random donor; instead, the blood type of donor is matched with the recipient prior transfusion to reduce the risk of complications. Although examples can be found in various areas of medicine, the role of precision medicine in everyday healthcare is relatively limited. Researchers are significantly working to expand this approach in many areas of healthcare and health in the coming years.
Get the Sample Pages of Report for More [email protected] [To enable links contact MENAFN]
The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market. NGS technology provides the data related to the patient’s genetic makeup along with response of drugs on the patient, thereby raising the development of precision medicine for the treatment of diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is analyzed to play a significant role in the advancement of personalized therapeutics and diagnostics over the forecast period. Apart from the benefits offered by the precision medicine, they are highly expensive due to the application of high-end computational methods to examine individual genes projected to hinder the market growth.
North America dominated the global precision medicine market with revenue share of nearly 40% in 2019 and expected to grow at an escalating pace during the forecast period. Technological advancement along with the presence of major players in the region contributes significantly towards the growth of the region. However, the Asia Pacific seeks to be the most opportunistic region in the precision medicine market owing to increasing cases of cancer and other diseases along with the health awareness among people.
View Full Report with Complete ToC @ [To enable links contact MENAFN]
- In 2019, North America captured more than 40% of the overall market value share in 2019 and projected to maintain its position in the coming years. Increasing prevalence of cancer along with the presence of key market players in the region expected to be the key factors contributing for the market growth in
Ross University School of Veterinary Medicine Partners With MANRRS to Increase Diversity in Veterinary Profession
Pet owners represent a much more diverse population than the veterinary professionals who care for them and their animals, a gap the American Veterinary Medicine Association (AVMA)1 and the Association of American Veterinary Colleges (AAVMC) 2 are working hard to fill. Ross University School of Veterinary Medicine (RUSVM) is committed to being part of the solution and is proud to announce a new partnership with Minorities in Agriculture, Natural Resources and Related Sciences (MANRRS). This collaboration will further RUSVM’s long-term commitment to increase diversity in the veterinary profession and strengthen the pipeline of highly qualified, diverse students pursuing an education in veterinary medicine.
The partnership will introduce RUSVM to MANRRS chapters across the U.S. with MANRRS members gaining access to exclusive webinars and virtual workshops from RUSVM to increase exposure to the profession. Additionally, qualified students may apply for a newly launched MANRRS scholarship. The partnership will also help establish a professional chapter of MANRRS at RUSVM that will create mentoring opportunities for current RUSVM students and enhanced networking opportunities. To learn more about this partnership, click here.
“It is vitally important that the field of veterinary medicine is representative of the communities that we serve, and Ross University School of Veterinary Medicine is thrilled to take this important step toward increasing diversity in the field,” said Sean Callanan, MVB, CERTVR, MRCVS, PHD, FRCPATH, DIPLECVP, dean of Ross University School of Veterinary Medicine. “As one of the most ethnically diverse AVMA-accredited veterinary schools, the partnership with MANRRS will provide new opportunities for prospective, current and former students, and pave the way for a more diverse workforce.”
According to an American Veterinary Medicine Association (AVMA) report, more than one-third of African Americans surveyed own a pet. However, the vast majority of practicing veterinarians in the U.S. are white3, highlighting a disparity in the diversity of the profession and the people that they serve.
“While facing the dismal reality that more than 85% of Veterinarians are white, MANRRS is committed to partnering with RUSVM to provide underrepresented students access to pursue a career in veterinary medicine,” said Ebony Webber, chief operating officer for MANRRS. “Provided that MANRRS is one of the only and largest organizations focused on diverse talent in agriculture, our student and professional members expect MANRRS to advocate for diversity, equity, and inclusion in areas where minorities are needed to help solve the world’s biggest challenges relating to animal health.”
RUSVM, supported by its parent company, Adtalem Global Education, is committed to cultivating a culture of diversity and inclusivity and creating a diverse global workforce that reflects that culture. To learn more about Adtalem’s commitment to diversity and inclusion, click here.
About Ross University School of Veterinary Medicine
Ross University School of Veterinary Medicine (RUSVM) is an institution of Adtalem Global Education (NYSE:ATGE, member S&, P MidCap 400 Index)). Founded in 1982, RUSVM is committed to preparing students to become members and leaders of the worldwide public and professional healthcare team and to advance human, animal and
Our virtual MedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support precision and personalized medicine.
One vexing part of any conversation on precision medicine and breakthrough therapies that have been developed and are continuing to work their way through clinical trials for cancer to rare disease is how to address the practical challenge of their high price tags. Although there are several models to cover the cost of these therapies such as Cigna’s Embarc Benefit Protection program, what happens when someone changes insurers when they change their job? What is fair for patients and what’s fair for companies? When do these conversations even start?
The panel, Reimbursement Models for Cell and Gene Therapies, will highlight some of the pros and cons of different models that are coming to market. Panelists include Laura Okpala, Director, Reimbursement Policy, Gilead Sciences, and Mark Trusheim, Strategic Director, NEWDIGS initiative at the MIT Center for Biomedical Innovation.
Here’s a preview of some of the sessions. Click here to see the agenda.
Interoperability Progress Report
How far have we progressed with sharing patient medical records? Patient data is key in unlocking riddles of medical science but interoperability is necessary to facilitate this. What companies are making an impact on a regional and national scale? What milestones are on the horizon? What obstacles continue to vex further advancement? How can we make medical records more accessible to patients?
Moderator: Elise Reuter, Senior Reporter, MedCity News
Kevin Chaney, Senior Program Manager, Office of the National Coordinator for Health IT
Ida Sim, M.D., Ph.D., Professor of Medicine, University of California, San Francisco
Niko Skievaski, Co-Founder and President, Redox
What It Takes To Build A Successful, Regional BioInnovation Hub
Philadelphia is one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session will be held as part of Venture Cafe Philadelphia.
(sponsored by IBX)
Lisa Dalton, Chief People Officer, Spark Therapeutics
Audrey Greenberg, Executive Managing Director, The Discovery Labs
Tiffany Wilson, President & CEO, University City Science Center
Moderator: Michelle Histand, Director of Innovation, Independence Blue Cross
Register now and be part of the conversation at INVEST Precision Medicine.